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This Biomedicine Select explores a cluster of recent papers that highlight traditional and new approaches to
treating a variety of diseases—from a small-molecule inhibitor to treat temporal lobe epilepsy to cell replacement
therapy for diabetes to a unique way to generate tumor-specific antigens.
Energetic Insights into Epilepsy
Epilepsy affects more than 50 million people worldwide and about 40% of
those with the disease continue to have seizures despite treatment with
antiepileptic medications or surgery. Some of these individuals are able to
reduce the number of seizures by adopting a ketogenic diet (in which no
carbohydrates are consumed, only fats and proteins), suggesting that the
glycolytic pathway may somehow be involved in epilepsy. Using a rat
(‘‘kindling’’) model of severe temporal lobe epilepsy, Garriga-Canut and col-
leagues (2006) investigate the link between glycolysis and epilepsy using
2-deoxy-D-glucose (2DG), a synthetic glucose analog that blocks glycolysis.
Treatment of the ‘‘kindling’’ rats with 2DG increased the threshold for sei-
zures induced by electrical stimuli and reduced the severity of subsequent
seizures. 2DG treatment also resulted in decreased expression of genes
encoding the neurotrophin BDNF and its receptor TrkB, which are usually
upregulated during seizures. This downregulation is mediated by the tran-
scription factor NRSF (neural-restrictive silencing factor), which recruits
the corepressor CtBP in an NADH-labile manner resulting in histone modifi-
cations that repress transcription. The authors propose that a 2DG-mediated decrease in glycolysis may reduce
NADH levels such that interactions between NRSF and CtBP are strengthened leading to enhanced repression of
BDNF signaling. 2DG is known to be well tolerated in humans having been tested in clinical trials for other purposes.
Although it is early days therapeutically speaking, the authors propose that 2DG could be the founding member of
a new class of antiepileptic drug whose therapeutic effect is mediated by targeting energy metabolism.
M. Garriga-Canut et al. (2006). Nat. Neurosci. Published online October 15, 2006 10.1038/nn1791.
Putting a Parasite to Work
Focusing on a much rarer form of epilepsy, MERFF (myoclonic epilepsy with ragged red fibers), Mahata et al. (2006)
turn to the protozoan parasite Leishmania to circumvent a mitochondrial mutation that causes this disorder. The mu-
tation—an A to G nucleotide switch at position 8344—in a mitochondrially encoded transfer RNA (tRNALys) leads to
reduced translation of mitochondrial mRNAs and accumulation of aberrant translation products, resulting in disease
pathology. Leishmania has evolved a specialized RNA import protein complex (RIC) in its mitochondrial inner mem-
brane that imports nuclear-encoded tRNAs into the parasite mitochondria. In their new work, Mahata and colleagues
use cultured cybrids (enucleated cells from MERFF patients fused with an immortalized cell line) to test whether
Leishmania’s RICs can circumvent the mitochondrial defect in MERFF cells. With live imaging and RNAi, the authors
show that fluorescently labeled RICs are associated with mitochondria in about 80% of MERFF cybrids within 24 hr
and that the association depends on caveolin-mediated endocytosis. In MERFF cybrids exposed to RICs, cytoplas-
mic tRNALys was found both in the cytosolic and mitochondrial fractions showing that RICs could import this tRNA
into human cell mitochondria. Twenty-four hours after RICs treatment, protein synthesis in MERFF cybrids was
restored almost to normal levels and aberrant translation products were no longer detected. RICs treatment also
led to restoration of oxidative phosphorylation in MERFF mitochondria (as demonstrated by increased cytochrome
oxidase complex IV activity, increased inner membrane potential, and enhanced oxygen uptake). That these benefits
were indeed due to RIC-mediated transport of tRNALys into MERFF mitochondria was demonstrated by blocking the
tRNA binding site of RICs and abrogating the improvement in mitochondrial physiology. Clearly these studies are
in vitro, and therapeutic application (presumably by injecting RICs into affected tissue such as muscle) remains in
the distant future. Given that RICs import other cytoplasmic tRNAs in addition to tRNALys into human mitochondria,
RIC treatment could combat a variety of severe disorders involving mitochondrial tRNA mutations.
B. Mahata et al. (2006). Science 314, 471–474.
A Hint of Sweet Success for Stem Cell Therapy
A key goal of cell replacement therapy is to coax human embryonic stem cells to differentiate into fully functional cells
that can be used to replace injured tissue in patients with a variety of diseases. An obvious target is diabetes where
loss of insulin-secreting b cells in the pancreatic islets leads to dependence on insulin injections. In a new study,
D’Amour and colleagues (2006) use the extensive literature about normal differentiation of embryonic endoderm
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into fetal pancreatic endocrine cells to design a series of culture conditions that in-
duce human embryonic stem cells to mimic the five key steps of normal pancreatic
differentiation. Using activin A and Wnt3a, to coax human embryonic stem cells to be-
come definitive endoderm (stage 1), the authors then used different combinations of
retinoic acid, cyclopamine, and FGF10 to drive the cells through stages 2 and 3, and
then a cocktail of growth factors and other molecules to drive their differentiation into
pancreatic endoderm (stage 4) and finally endocrine precursor cells (stage 5). They
then tested whether stage 5 pancreatic endocrine cells (at day 15 of differentiation)
could synthesize insulin de novo and release it into the medium in response to glucose
or other stimuli. Stage 5 cells produced combinations of the correct pancreatic hor-
mones including insulin, glucagon, somatostatin, and pancreatic polypeptide, and
they coexpressed key pancreatic markers (PAX6, ISLET1, and synaptophysin). About
7% to 12% of stage 5 endocrine cells expressed insulin (contained in typical secretory
granules) and the total insulin content was similar to that of normal adult human pan-
creatic islets. This is an advance over previous studies where the insulin content of
pancreatic cells derived from human embryonic stem cells was very low. Several dif-
ferent stimuli (depolarization by blocking KATP channels; treatment with cAMP), but not glucose, induced stage 5 in-
sulin-expressing cells to release insulin into the medium. The authors propose that the inability of these pancreatic
endocrine cells to release insulin in response to glucose (a key requirement for diabetes cell therapy) may reflect their
immaturity. Indeed, it takes 12 to 16 weeks of embryonic development for normal human fetal pancreatic islets to
mature sufficiently to release insulin in response to glucose. Perhaps with a little more tweaking of culture conditions
and a lot more patience, human embryonic stem cells may be induced to become fully mature pancreatic b islet cells,
a big step forward on the road to cell therapy for diabetes.
K.A. D’Amour et al. (2006). Nat. Biotechnol. Published online October 19, 2006. 10.1038/nbt1259.
Cosmc Interference Aids Antitumor Antibodies
Monoclonal antibodies directed against tumor antigens have long been touted as magic bullets
that could deliver antitumor toxins to cancer cells expressing the appropriate tumor antigen.
Now, Schietinger et al. (2006) describe an unusual way to create a powerful new antigenic epi-
tope in a wild-type protein that drives production of a high-affinity antibody. Using mice bearing
an aggressive fibrosarcoma (Ag104A), the investigators detected in these animals a high-affinity
antibody (237 mAb) directed against this fibrosarcoma (but not other tumors or normal mouse
tissue) that reduced tumor growth when administered to other syngeneic tumor-bearing mice.
Seeking the antigenic epitope that could induce such a useful antitumor antibody, the investi-
gators homed in on a 10-amino acid extracellular fragment of a sialomucin-like transmembrane
glycoprotein called OTS8. They pinpointed a posttranslational modification in this fragment
resulting in decreased O-linked glycosylation at threonine 77. The shortened O-linked
glycan—composed primarily of N-acetylgalactosamine (GalNAc) and lacking the galactose
and sialic acid residues of wild-type (nonantigenic) OTS8—was caused by loss of activity of
a glycosyltransferase. Intriguingly, loss of activity was due not to a mutation in the glycosyltrans-
ferase but rather to a mutation in a chaperone protein, Cosmc, that is required for this enzyme’s
activity. Indeed, overexpression of mouse wild-type Cosmc in Ag104A fibrosarcoma cells induced them to express
wild-type OTS8 lacking the highly antigenic epitope such that they were no longer recognized by 237 mAb. Notably,
mutant Cosmc alters the glycosylation not only of OTS8 but also of other glycoproteins in the Ag104A fibrosarcoma,
creating not one but potentially many new antigenic epitopes. Furthermore, Cosmc mutations have been identified in
other mouse and human tumors including neuroblastoma, colon cancer, and T cell leukemia. Cosmc mutations gen-
erating new highly antigenic glycopeptide epitopes may turn out to be a feature of many tumors, suggesting that
monoclonal antibodies directed against these antigens could be used in passive immunotherapy to combat not
one but many different tumors.
A. Schietinger et al. (2006). Science 314, 304–308.
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